PURE Bioscience Reports Fiscal 2026 Financial Results
Key Highlights
- ➤Net product sales $2.315 million, up $117,000 year-over-year
- ➤Net loss widened to $2.483 million from $2.399 million
- ➤Operating cash use improved to $1.97 million from $2.0 million
- ➤Current liabilities rose to $4.371 million, including $1.015 million past-due notes
- ➤Dairy product penetration lagged amid slow customer adoption and industry consolidation
Expert Statements
Jeff Kitchell, Chief Executive Officer of PURE Bioscience
“We are up year-over-year despite being a challenging year, with the macro environment causing increased expenses and foodborne outbreaks severely disrupting the food industry.”
Jeff Kitchell, Chief Executive Officer of PURE Bioscience
“Although our growth didn’t meet expectations, our focus remains on reducing costs and converting more opportunities into revenue.”
Jeff Kitchell, Chief Executive Officer of PURE Bioscience
“We continue to strengthen and expand our technology across our partnerships and to provide our distributor network with technical support and marketing tools for the industries they serve.”
Jeff Kitchell, Chief Executive Officer of PURE Bioscience
“Our product penetration in the dairy industry has not met expectations due to slow customer adoption and industry consolidation.”
Jeff Kitchell, Chief Executive Officer of PURE Bioscience
“We are strengthening all our business development models, and adjustments are underway that better serve our customers and partners.”
Jeff Kitchell, Chief Executive Officer of PURE Bioscience
“We continue to prove that our SDC products are superior to the current chemistries in use.”
PURE Bioscience, Inc. (OTCQB: PURE ) (“PURE,” the “Company,” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC ) antimicrobial, today reported financial results for the fiscal year ended July 31, 2026.
* Net product sales were $2,315,000 and $2,198,000 for the fiscal years ended July 31, 2026 and 2025, respectively. The $117,000 increase was attributable to increased sales across our end-user network.
Get started
Create a free account to read the full story.